Skip to main content
Premium Trial:

Request an Annual Quote

Scienion, Grenier Bio-One Collaborate on Rapid Multiplex Dx for Infectious Disease

NEW YORK (GenomeWeb) – European firms Scienion and Grenier Bio-One today announced a collaboration to co-develop rapid, multiplexed diagnostic tests.

The partners said in a statement they would develop new tests for human pathogens that will yield test results within 75 minutes.

Financial and other details of the agreement were not disclosed.

The deal brings together Scienion's sciFlexarrayer liquid handling technology and Grenier's PCR-based Genspeed pathogen detection platform. Kremsmünster, Austria-based Grenier has already launched a methicillin-resistant Staphylococcus aureus test, the Genspeed MRSA.

The agreement is the latest in a string of technology partnerships for Berlin-based Scienion this year. In September, the firm partnered with Australian firm Axxin to develop a multiplexed microarray analysis system. In July, it partnered with Australian reagent maker Anteo Technologies to improve the shelf life of protein microarrays. And in June, Scienion agreed to integrate sciFlexarrayer into QuantuMDx's nanowire array technology and commercialize the biosensor.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.